• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

937270-47-8 (SB1317)

1

Identification

SB1317 SB1317
Name SB1317
Formula C23H24N4O
MW 372.46
CAS No. 937270-47-8
EINECS
Smiles CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2
Synonyms TG02;SB 1317;TG 02;SB-1317;TG-02;
InChI InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+
2

Introduction

SB1317(TG-02) is a novel small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively. IC50 Value: 13/73/56 nM(CDK2/JAK2/FLT3) Target: CDK2/JAK2/FLT3 TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.

Background Information

SB1317 (TG02) is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. SB1317 dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). In vivo, SB1317 (TG02) exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma. ......by AbMole BioScience
TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. ......by AdooQ BioScience, LLC
TG02, also known as SB1317,  is  a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferativ ......by BOC Sciences
SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. ......by MedChemexpress Co., Ltd.
TG02, also known as SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. ......by MedKoo Biosciences, Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white solid EBNumber:EB000022616

Storage condition

Storage condition:Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). Stock solution storage:0 - 4 C for short term (days to weeks), or -20 C for long term (months). Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. by MedKoo Biosciences, Inc.

Solubility

Soluble in DMSO, not in water by MedKoo Biosciences, Inc.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
SB1317 Tragara Pharmaceuticals Inc Chronic lymphocytic leukemia 2012/9/30 2014/8/31 Phase 1 Clinical
SB1317 Tragara Pharmaceuticals Inc Hematological neoplasm 2010/8/31 2013/7/31 Phase 1 Clinical
SB1317 - Phase 2
7

Safety Data of SB1317

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AbMole BioScience 10mg/USD220(Out of stock) USA
AdooQ BioScience, LLC 5mg/USD90() USA
Aladdin 5mg/RMB2024();10mg/RMB3320();100mg/RMB11858() China
Apexbio Technology LLC 5mg/USD107(Ship Within 10-14 Days) USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD110();10mg/USD150() USA
MedChemexpress Co., Ltd. 5mg/USD110();10mg/USD150() USA
MedKoo Biosciences, Inc. 5mg/USD90() USA
Pure Chemistry Scientific Inc. 10mg/USD104(In stock) USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD110();10mg/USD150() China
eNovation Chemicals LLC 25mg/USD385() USA
10

Related Products

Other Forms of 937270-47-8

Name CAS No Formula MW

Recommended Compounds in CDK FLT3 JAK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
Mocetinostat 726169-73-9 C23H20N6O 396.44
CAL-101 870281-82-6 C22H18FN7O 415.42
SNX-2112 908112-43-6 C23H27F3N4O3 464.48
FK866 658084-64-1 C24H29N3O2 391.51
17-AAG (Hydrochloride) 911710-03-7 C31H44ClN3O8 622.15
Vismodegib 879085-55-9 C19H14Cl2N2O3S 421.3
Dinaciclib 779353-01-4 C21H28N6O2 396.49
MEK162 606143-89-9 C17H15BrF2N4O3 441.23
AT7519 844442-38-2 C16H17Cl2N5O2 382.24
Chlorambucil 305-03-3 C14H19Cl2NO2 304.21
PCI-24781 783355-60-2 C21H23N3O5 397.42
IC-87114 371242-69-2 C22H19N7O 397.43
Pentostatin 53910-25-1 C11H16N4O4 268.27
Alvespimycin 467214-20-6 C32H48N4O8 616.75
Lenalidomide (hydrochloride) 1243329-97-6 C13H14ClN3O3 295.72
Doxorubicin (hydrochloride) 25316-40-9 C27H30ClNO11 579.98
Salirasib 162520-00-5 C22H30O2S 358.54
XL413 1169558-38-6 C14H12ClN3O2 289.72
XL413 (hydrochloride) 1169562-71-3 C14H13Cl2N3O2 326.18
Duvelisib 1201438-56-3 C22H17ClN6O 416.863
11

Route of Synthesis

12

References

13

More Information

SB1317

Tags: buy 937270-47-8 IC50 | 937270-47-8 price | 937270-47-8 cost | 937270-47-8 solubility | 937270-47-8 purchase | 937270-47-8 manufacturer | 937270-47-8 research buy | 937270-47-8 order | 937270-47-8 MSDS | 937270-47-8 chemical structure | 937270-47-8 Storage condition | 937270-47-8 molecular weight | 937270-47-8 mw | 937270-47-8 datasheet | 937270-47-8 supplier | 937270-47-8 cell line | 937270-47-8 NMR | 937270-47-8 MS | 937270-47-8 IR | 937270-47-8 solubility | 937270-47-8 Safe information | 937270-47-8 Qc and Spectral Information | 937270-47-8 Clinical Information | 937270-47-8 Clinical Trial | 937270-47-8 Route of Synthesis | 937270-47-8 storage condition | 937270-47-8 diseases and conditions | 937270-47-8 flash point | 937270-47-8 boiling point | 937270-47-8 melting point | 937270-47-8 storage condition | 937270-47-8 brand